A meta-analysis of SGLT2 inhibitors had the largest and most consistent effect in reducing the relative risk of heart failure hospitalization (31%) and kidney disease progression (45%), however, SGLT2 inhibitors reduced MACE by 11%, with the benefits observed only in patients with atherosclerotic cardiovascular disease (Zelniker et al., 2019). The gene discussed is SLC5A2; the disease is heart failure.